Stifel Reiterates Buy Rating on Cerevel Therapeutics (CERE), Epilepsy Data From REALIZE Ph2 Study Remains Important Catalyst
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $50.00 price target on Cerevel Therapeutics (NASDAQ: CERE), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
